Amgen shows up in
42%
Amgen appears in 33% of buyer questions and 100% of direct comparison questions that include Amgen. Regeneron Pharmaceuticals appears in 33% of buyer questions.
AI search report
See when AI mentions Amgen, where buyer questions leave you out, and what to fix first so more buyers discover you before competitors.
What buyers see in AI search
Amgen shows up in
42%
Amgen appears in 33% of buyer questions and 100% of direct comparison questions that include Amgen. Regeneron Pharmaceuticals appears in 33% of buyer questions.
Buyer questions missed
58%
Amgen is left out of 58% of the buyer and comparison questions checked.
Who AI recommends instead
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is the competitor AI surfaces most often here.
How AI describes you vs competitors
| What buyers care about | What this means | Amgen | Regeneron Pharmaceuticals | Gilead Sciences | Vertex Pharmaceuticals |
|---|---|---|---|---|---|
| Gmp Certifications | AI gives Regeneron Pharmaceuticals more credit for gmp certifications than Amgen. | Barely associated | Clearly associated | Barely associated | Barely associated |
| Clinical Trial Experience | AI sometimes connects Amgen with clinical trial experience, but the story is not dominant yet. | Sometimes associated | Barely associated | Barely associated | Barely associated |
| Regulatory Approvals | AI has little clear evidence connecting Amgen with regulatory approvals. | Barely associated | Barely associated | Barely associated | Barely associated |
| Manufacturing Capacity | AI has little clear evidence connecting Amgen with manufacturing capacity. | Barely associated | Barely associated | Barely associated | Barely associated |
| Quality Systems | AI gives Gilead Sciences more credit for quality systems than Amgen. | Barely associated | Barely associated | Sometimes associated | Barely associated |
| Scale-up Capabilities | AI gives Regeneron Pharmaceuticals more credit for scale-up capabilities than Amgen. | Barely associated | Sometimes associated | Barely associated | Barely associated |
Buyer questions you are missing
These are high-intent questions where AI did not mention Amgen. Each one can become a clear answer page AI can trust and reuse, supported by evidence from Amgen's site.
Buyer question
Amgen was not mentioned in this AI answer.
See the AI answerBuyer question
Amgen was not mentioned in this AI answer.
See the AI answerBuyer question
Amgen was not mentioned in this AI answer.
See the AI answerBuyer question
Amgen was not mentioned in this AI answer.
See the AI answerComparison question
Amgen was not mentioned in this AI answer.
See the AI answerComparison question
Amgen was not mentioned in this AI answer.
See the AI answerWhat to fix first
Readable turns missed buyer questions into pages AI can trust, clearer evidence buyers can verify, and comparison answers that make it easier for AI tools to recommend you.
Close the Gmp Certifications gap before competitors keep winning the recommendation.: Buyers are asking about Gmp Certifications, but your homepage barely explains it. AI answers currently connect Regeneron Pharmaceuticals more strongly with that need.
Create dedicated comparison pages positioning Amgen against Vertex and Gilead on therapeutic breadth and manufacturing scale; ensure these pages cite Amgen's oncology, immunology, and rare disease portfolios to capture disease-specific AI recommendations
Develop content establishing Amgen's supply chain reliability and hospital distribution network as primary differentiators; target citations in hospital formulary, cold-chain logistics, and global distribution authority sources to compete with Roche and Novartis positioning
Build category authority pages linking Amgen's manufacturing capabilities to specific therapeutic modalities (monoclonal antibodies, recombinant proteins, biosimilars); ensure technical documentation and regulatory approval data are indexed and cited by AI systems to address the 0% association with GMP certifications and regulatory attributes
Regeneron appears in 5 of 6 comparison queries while Amgen appears in only 3; Amgen is absent from pipeline, rare disease, and antiviral comparisons where competitors establish therapeutic credibility
What you’ll see in the AI search review
In one review, we’ll show where Amgen is missing, which competitors AI is recommending instead, and the first pages or evidence updates most likely to help you show up.
The buyer questions where Amgen is left out.
The competitor claims AI is repeating instead.
The first fixes most likely to help Amgen show up.
Fix the buyer moments AI is missing
Bring this report to a short review with Readable. You will leave knowing the buyer questions, evidence gaps, and answer pages that matter most.
Improve my AI visibility